drugset / Trial / NCT00101075
Title XELOX FOR SALIVARY GLAND CANCERS
Phase 2
Terminated
9 enrolled
Dana-Farber Cancer Institute
National Cancer Institute (NCI) · collabSanofi-Synthelabo · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find out how effective oxaliplatin and capecitabine are against advanced cancer of the salivary gland. The safety of this treatment as well as how long the cancer responds or stays in a stable state due to the treatment will also be studied.
Timeline
- Start
- 2004-10
- Primary completion
- 2007-03
- Completion
- 2008-03
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1700 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |